EcoDrugPlus

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSACLG00000005801
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSACLG00000012760
Gene Symbol: PSMA4
4 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSACLG00000021904
Gene Symbol: PSMA8
3 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSACLG00000009055
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSACLG00000018213
Gene Symbol: PSMB11B
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSACLG00000005086
Gene Symbol: PSMB2
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSACLG00000009343
Gene Symbol: PSMB3
1 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSACLG00000009982
Gene Symbol: PSMB4
1 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSACLG00000010267
Gene Symbol: PSMD4A
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSACLG00000023769
Gene Symbol: PSMC1
3 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSACLG00000012004
Gene Symbol: PSMC2
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSACLG00000009092
Gene Symbol: PSMC3
3 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).